Scot A. Marsters mainly investigates Molecular biology, Apoptosis, Immunology, Cell biology and Fas receptor. His work in Molecular biology addresses subjects such as Tumor necrosis factor alpha, which are connected to disciplines such as B-cell activating factor. The Apoptosis study combines topics in areas such as Mediator and Intracellular.
His Immunology study integrates concerns from other disciplines, such as 5-HT5A receptor, Decoy Receptor 1, Growth factor receptor and Decoy receptors. His work on Endoplasmic reticulum as part of his general Cell biology study is frequently connected to Tumor Necrosis Factor Decoy Receptors, thereby bridging the divide between different branches of science. His work focuses on many connections between Fas receptor and other disciplines, such as Receptor, that overlap with his field of interest in Natural killer cell and Decoy receptor 3.
Scot A. Marsters mostly deals with Molecular biology, Antibody, Biochemistry, Cell biology and Apoptosis. His Molecular biology research includes elements of Tumor necrosis factor alpha, DNA, Receptor, B-cell activating factor and Binding site. His Tumor necrosis factor alpha study which covers Pharmacology that intersects with Agonist.
He has researched Antibody in several fields, including Antigen and Virology. His Cell biology study combines topics from a wide range of disciplines, such as XBP1 and Programmed cell death. His studies examine the connections between Apoptosis and genetics, as well as such issues in Cancer cell, with regards to Tumor microenvironment.
His primary areas of study are Cell biology, Endoplasmic reticulum, Apoptosis, Unfolded protein response and Receptor. His Cell biology research incorporates elements of XBP1 and Programmed cell death. His research investigates the connection with Endoplasmic reticulum and areas like Transcription factor which intersect with concerns in Kinase, Phosphorylation, Cancer cell and Cancer research.
His study looks at the intersection of Apoptosis and topics like Ectodomain with Cytoprotection. His studies deal with areas such as Epitope, Antibody, Tissue homeostasis and Cytotoxicity as well as Receptor. His biological study spans a wide range of topics, including Tumor necrosis factor alpha, Pharmacology and Recombinant DNA.
Scot A. Marsters mainly focuses on Cell biology, Apoptosis, Programmed cell death, Receptor and Unfolded protein response. His Apoptosis study incorporates themes from Cadherin and Cell fate determination. His study in Programmed cell death is interdisciplinary in nature, drawing from both Cancer cell, Ectodomain, Cell membrane, Cytotoxicity and Kinase.
The study incorporates disciplines such as Tissue homeostasis, Actin cytoskeleton, Cytoskeleton, Signal transduction and Actin in addition to Receptor. Scot A. Marsters has included themes like Proteostasis, Transcription factor and Phosphorylation in his Unfolded protein response study. His research integrates issues of Caspase, Mediator and Intracellular in his study of Endoplasmic reticulum.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi;Roger C. Pai;Sharon Fong;Susan Leung.
Journal of Clinical Investigation (1999)
Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family *
Robert M. Pitti;Scot A. Marsters;Siegfried Ruppert;Christopher J. Donahue.
Journal of Biological Chemistry (1996)
Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors
James P. Sheridan;Scot A. Marsters;Robert M. Pitti;Austin Gurney.
Science (1997)
Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer
Robert M. Pitti;Scot A. Marsters;David A. Lawrence;Margaret Roy.
Nature (1998)
Designing CD4 immunoadhesins for AIDS therapy
Daniel J. Capon;Steven M. Chamow;Joyce Mordenti;Scot A. Marsters.
Nature (1989)
Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions
David Lawrence;Zahra Shahrokh;Scot Marsters;Kirsten Achilles.
Nature Medicine (2001)
Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen
Douglas H. Smith;Randal A. Byrn;Scot A. Marsters;Timothy Gregory.
Science (1987)
A novel receptor for Apo2L/TRAIL contains a truncated death domain
S.A. Marsters;J.P. Sheridan;R.M. Pitti;A. Huang.
Current Biology (1997)
Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.
Steven Shak;Daniel J. Capon;Renate Hellmiss;Scot A. Marsters.
Proceedings of the National Academy of Sciences of the United States of America (1990)
Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.
A Ashkenazi;S A Marsters;D J Capon;S M Chamow.
Proceedings of the National Academy of Sciences of the United States of America (1991)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
MIT
Gilead Sciences
Johnson & Johnson
Genentech
University of California, San Francisco
LabCorp (United States)
Genentech
Genentech
Beth Israel Deaconess Medical Center
École Polytechnique Fédérale de Lausanne
Pennsylvania State University
University of Zurich
Worcester Polytechnic Institute
Beijing Normal University
West Pomeranian University of Technology
Wellcome Sanger Institute
INRAE : Institut national de recherche pour l'agriculture, l'alimentation et l'environnement
Ghent University
Drexel University
National Institutes of Health
University of Oxford
Utrecht University
University of Washington
Pepperdine University
Catholic University of America